Bardoxolone Methyl for the treatment of chronic kidney disease (CKD) caused by Alport Syndrome

Bardoxolone methyl is in clinical development for the treatment of patients aged 12 years and
older with Alport syndrome. Alport syndrome is a genetic condition characterized by kidney
disease, hearing loss, and eye abnormalities. It is caused by a defect (mutation) in a gene for a
protein in the connective tissue, called collagen. There are currently no licensed treatments to
treat the underlying mechanism of the condition although some of the symptoms can be managed
to slow down the progression of the disease. The condition can become life threatening unless
patients receive dialysis treatments several times a week (patients are connected to a machine
for several hours that removes waste products from their blood) or receive a kidney transplant.